Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: In non-small cell lung cancer (NSCLC) patients treated by immune checkpoint inhibitors (ICIs), tumor mutation burden (TMB) has been found to have predictive potential for survival. When compared to TMB detection in tissue (tTMB), detecting TMB in the blood (bTMB) has practical advantages...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nan, Zhang, Jinwei, Wang, Guoqing, He, Xin, Mi, Yin, Cao, Ying, Yu, Xiaoxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864144/
https://www.ncbi.nlm.nih.gov/pubmed/35223476
http://dx.doi.org/10.3389/fonc.2022.795933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864144/
https://www.ncbi.nlm.nih.gov/pubmed/35223476
http://dx.doi.org/10.3389/fonc.2022.795933

Ejemplares similares